Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Short Interest Up 19.5% in February

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) was the target of a significant increase in short interest in the month of February. As of February 28th, there was short interest totalling 4,900 shares, an increase of 19.5% from the February 13th total of 4,100 shares. Based on an average daily volume of 33,200 shares, the short-interest ratio is currently 0.1 days. Approximately 0.3% of the company’s shares are sold short.

Analyst Upgrades and Downgrades

Separately, StockNews.com began coverage on Galmed Pharmaceuticals in a research report on Wednesday, March 12th. They issued a “sell” rating for the company.

Galmed Pharmaceuticals Price Performance

GLMD stock traded down $0.25 during trading on Wednesday, reaching $2.26. 198,198 shares of the stock traded hands, compared to its average volume of 892,533. The business’s 50 day moving average price is $2.52 and its 200-day moving average price is $3.44. Galmed Pharmaceuticals has a 52-week low of $1.67 and a 52-week high of $23.80. The firm has a market capitalization of $1.46 million, a PE ratio of -0.14 and a beta of 0.72.

Institutional Investors Weigh In On Galmed Pharmaceuticals

An institutional investor recently bought a new position in Galmed Pharmaceuticals stock. Schonfeld Strategic Advisors LLC purchased a new stake in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 25,400 shares of the biopharmaceutical company’s stock, valued at approximately $81,000. Schonfeld Strategic Advisors LLC owned 3.97% of Galmed Pharmaceuticals at the end of the most recent quarter. 76.14% of the stock is owned by hedge funds and other institutional investors.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.